These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 11343384)
1. High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Barone S; Baer MR; Sait SN; Lawrence D; Block AW; Wetzler M Am J Hematol; 2001 Jun; 67(2):119-24. PubMed ID: 11343384 [TBL] [Abstract][Full Text] [Related]
2. Idarubicin in blastic crisis of chronic myelogenous leukemia. Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446 [TBL] [Abstract][Full Text] [Related]
3. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation]. Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase]. Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563 [TBL] [Abstract][Full Text] [Related]
5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346 [TBL] [Abstract][Full Text] [Related]
6. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589 [TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664 [TBL] [Abstract][Full Text] [Related]
8. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Deau B; Nicolini FE; Guilhot J; Huguet F; Guerci A; Legros L; Pautas C; Berthou C; Guyotat D; Cony-Makhoul P; Gardembas M; Michallet M; Hayette S; Cayuela JM; Weiss IR; Réa D; Castaigne S; Mahon FX; Guilhot F; Rousselot P Leuk Res; 2011 Jun; 35(6):777-82. PubMed ID: 21145590 [TBL] [Abstract][Full Text] [Related]
9. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553 [TBL] [Abstract][Full Text] [Related]
10. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747 [TBL] [Abstract][Full Text] [Related]
11. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320 [TBL] [Abstract][Full Text] [Related]
12. Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Karbasian-Esfahani M; Wiernik PH; Novik Y; Paietta E; Dutcher JP Cancer; 2004 Sep; 101(6):1414-9. PubMed ID: 15368329 [TBL] [Abstract][Full Text] [Related]
13. [Multicenter randomized control trial on safety of domestic idarubicin for acute leukemia]. Liu Y; Ke XY; Ma J; Shen ZX; Zhang XH; Du X; Zhao YM; Lv JQ; Zhan ZM; Zeng XY; Xu XH; Lu ZS Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):706-8. PubMed ID: 17274381 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma. Brusamolino E; Passamonti F; Pagnucco G; Castagnola C; Lazzarino M; Bernasconi C Haematologica; 1998 Apr; 83(4):323-8. PubMed ID: 9592982 [TBL] [Abstract][Full Text] [Related]
15. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136 [TBL] [Abstract][Full Text] [Related]
16. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center. Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808 [No Abstract] [Full Text] [Related]
17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376 [TBL] [Abstract][Full Text] [Related]
18. Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial. Schneller F; Schuler M; Schumacher K; Thaler J; Peschel C; Huber C; Aulitzky W Ann Hematol; 1998 Nov; 77(5):225-9. PubMed ID: 9858148 [TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G; Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477 [TBL] [Abstract][Full Text] [Related]
20. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]